Asymmetric Total Synthesis of (+)-Coprophilin

Shiina, Isamu; Umezaki, Yuma; Murata, Takatsugu; Suzuki, Kyohei; Tonoi, Takayuki

doi:10.1055/s-0036-1591866

Cited by 9 publications

(17 citation statements)

References 1 publication

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We then examined whether KIT activated downstream molecules on the Golgi in leukemia cells. To resolve this question, we used inhibitors of intracellular trafficking, such as brefeldin A (BFA), 2-methylcoprophilinamide (M-COPA) (inhibitors of ER export to the Golgi) [27, 34, 35, 41], monensin (an inhibitor of intra -Golgi trafficking) [26, 42], and bafilomycin A1 (BafA1, an inhibitor of endosome-to-lysosome trafficking) [24, 43]. In Kasumi-1 and HMC-1.1, treatment with BFA or M-COPA significantly increased colocalization of KIT with an ER marker, calnexin (Fig.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells

Obata¹,

Hara²,

Shiina³

et al. 2019

Cell Commun Signal

Self Cite

View full text Add to dashboard Cite

Background KIT tyrosine kinase is expressed in mast cells, interstitial cells of Cajal, and hematopoietic cells. Permanently active KIT mutations lead these host cells to tumorigenesis, and to such diseases as mast cell leukemia (MCL), gastrointestinal stromal tumor (GIST), and acute myeloid leukemia (AML). Recently, we reported that in MCL, KIT with mutations ( D816V , human; D814Y , mouse) traffics to endolysosomes (EL), where it can then initiate oncogenic signaling. On the other hand, KIT mutants including KIT D814Y in GIST accumulate on the Golgi, and from there, activate downstream. KIT mutations, such as N822K , have been found in 30% of core binding factor-AML (CBF-AML) patients. However, how the mutants are tyrosine-phosphorylated and where they activate downstream molecules remain unknown. Moreover, it is unclear whether a KIT mutant other than KIT D816V in MCL is able to signal on EL. Methods We used leukemia cell lines, such as Kasumi-1 ( KIT N822K , AML), SKNO-1 ( KIT N822K , AML), and HMC-1.1 ( KIT V560G , MCL), to explore how KIT transduces signals in these cells and to examine the signal platform for the mutants using immunofluorescence microscopy and inhibition of intracellular trafficking. Results In AML cell lines, KIT N822K aberrantly localizes to EL. After biosynthesis, KIT traffics to the cell surface via the Golgi and immediately migrates to EL through endocytosis in a manner dependent on its kinase activity. However, results of phosphorylation imaging show that KIT is preferentially activated on the Golgi. Indeed, blockade of KIT N822K migration to the Golgi with BFA/M-COPA inhibits the activation of KIT downstream molecules, such as AKT, ERK, and STAT5, indicating that KIT signaling occurs on the Golgi. Moreover, lipid rafts in the Golgi play a role in KIT signaling. Interestingly, KIT V560G in HMC-1.1 migrates and activates downstream in a similar manner to KIT N822K in Kasumi-1. Conclusions In AML, KIT N822K mislocalizes to EL. Our findings, however, suggest that the mutant transduces phosphorylation signals on lipid rafts of the Golgi in leukemia cells. Unexpectedly, the KIT V560G signal platform in MCL is similar to that of KIT N822K in AML. These observations provide new insights into the pathogenic role of KIT mutants as well as that of other mutant molecules. Electronic supplementary material The online version of this article (10.1186/s12964-01...

show abstract

Section: Resultsmentioning

confidence: 99%

“…Bafilomycin A1, brefeldin A (Sigma, St. Louis, MO), monensin (Biomol, Exeter, UK), and cer-C6 (Cayman Chemical) were dissolved in ethanol. M-COPA (also known as AMF-26) was synthesized as previously described [34, 35] and dissolved in DMSO.…”

Section: Methodsmentioning

confidence: 99%

N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells

Obata¹,

Hara²,

Shiina³

et al. 2019

Cell Commun Signal

Self Cite

View full text Add to dashboard Cite

show abstract

“…BFA (Sigma-Aldrich, St. Louis, MO) and monensin (Biomol, Hamburg, Germany) were dissolved in ethanol or methanol, respectively. M-COPA (also known as AMF-26) was synthesized as previously described 59 , 60 and dissolved in DMSO.…”

Section: Methodsmentioning

confidence: 99%

FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells

Yamawaki¹,

Shiina

Murata

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

FMS-like tyrosine kinase 3 (FLT3) in hematopoietic cells binds to its ligand at the plasma membrane (PM), then transduces growth signals. FLT3 gene alterations that lead the kinase to assume its permanently active form, such as internal tandem duplication (ITD) and D835Y substitution, are found in 30–40% of acute myelogenous leukemia (AML) patients. Thus, drugs for molecular targeting of FLT3 mutants have been developed for the treatment of AML. Several groups have reported that compared with wild-type FLT3 (FLT3-wt), FLT3 mutants are retained in organelles, resulting in low levels of PM localization of the receptor. However, the precise subcellular localization of mutant FLT3 remains unclear, and the relationship between oncogenic signaling and the mislocalization is not completely understood. In this study, we show that in cell lines established from leukemia patients, endogenous FLT3-ITD but not FLT3-wt clearly accumulates in the perinuclear region. Our co-immunofluorescence assays demonstrate that Golgi markers are co-localized with the perinuclear region, indicating that FLT3-ITD mainly localizes to the Golgi region in AML cells. FLT3-ITD biosynthetically traffics to the Golgi apparatus and remains there in a manner dependent on its tyrosine kinase activity. Tyrosine kinase inhibitors, such as quizartinib (AC220) and midostaurin (PKC412), markedly decrease FLT3-ITD retention and increase PM levels of the mutant. FLT3-ITD activates downstream in the endoplasmic reticulum (ER) and the Golgi apparatus during its biosynthetic trafficking. Results of our trafficking inhibitor treatment assays show that FLT3-ITD in the ER activates STAT5, whereas that in the Golgi can cause the activation of AKT and ERK. We provide evidence that FLT3-ITD signals from the early secretory compartments before reaching the PM in AML cells.

show abstract

Section: Chemicalsmentioning

confidence: 99%

FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells

Yamawaki¹,

Shiina

Murata

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

FMS-like tyrosine kinase 3 (FLT3) in hematopoietic cells binds to its ligand at the plasma membrane (PM), then transduces growth signals. FLT3 gene alterations that lead the kinase to assume its permanently active form, such as internal tandem duplication (ITD) and D835Y substitution, are found in 30~40% of acute myelogenous leukemia (AML) patients. Thus, the drugs for molecular targeting of FLT3 mutants have been developed for the treatment of AML. Several groups have reported that compared with wild-type FLT3 (FLT3-wt), FLT3 mutants are retained in organelles, resulting in low levels of PM localization of the receptor. However, the precise subcellular localization of mutant FLT3 remains unclear, and the relationship between oncogenic signaling and the mislocalization is not completely understood. In this study, we show that in cell lines established from AML patients, endogenous FLT3-ITD but not FLT3-wt clearly accumulates in the perinuclear region. Our co-immunofluorescence assays demonstrate that Golgi markers are co-localized with the perinuclear region, indicating that FLT3-ITD mainly localizes to the Golgi region in AML cells. FLT3-ITD biosynthetically traffics to the Golgi apparatus and remains there in a manner dependent on its tyrosine kinase activity. A tyrosine kinase inhibitor midostaurin (PKC412) markedly decreases in FLT3-ITD retention and increases in the PM levels of the mutant. FLT3-ITD activates downstream in the endoplasmic reticulum (ER) and the Golgi apparatus during its biosynthetic trafficking. Results of our trafficking inhibitor treatment assays show that FLT3-ITD in the ER activates STAT5, whereas that in the Golgi can cause the activation of AKT and ERK. We provide evidence that FLT3-ITD signals from the early secretory compartments before reaching the PM in AML cells.

show abstract

Asymmetric Total Synthesis of (+)-Coprophilin

Cited by 9 publications

References 1 publication

N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells

N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells

FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells

FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells

Contact Info

Product

Resources

About